2026 Q2 - tulosraportti
43 päivää sitten
‧42 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 000 | - | - | ||
| 65 042 | - | - | ||
| 100 000 | - | - | ||
| 100 000 | - | - | ||
| 100 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 5.5. | ||
2025 Q4 - tulosraportti 12.2. | ||
2025 Q3 - tulosraportti 23.10.2025 | ||
2025 Q2 - tulosraportti 10.7.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 päivä sittenI asked AI and got this answer: what is alligator expected to earn and when on the agreement regarding HLX22 According to the current agreement structure, the Swedish biotech company Alligator Bioscience is entitled to 35% of all milestone payments and royalties that the company AbClon receives from Shanghai Henlius Biotech for the development and sale of HLX22. Following a major strategic realignment in the summer of 2026, where Alligator stopped the in-house development of their previous lead candidate mitazalimab, the HLX22 agreement now constitutes the single most important value creator for the company. Here are the details on what Alligator is expected to earn, as well as when the money will arrive: Expected revenues (What can they earn?) • Historical milestones: Alligator has so far received a total of 3 million USD in early milestone payments under the agreement. • Effective royalty rate: The agreement ensures Alligator an effective royalty of 1.5% to 2.0% (more precisely up to 1.75%) of the total global net sales of HLX22. • Annual potential at peak sales (Peak Sales): Alligator estimates itself that when HLX22 is fully rolled out on the market, it will be able to generate 150 to 450 million Swedish kronor (SEK) annually in pure royalty income – based solely on the gastric cancer indication. • No costs: The absolute major financial advantage is that Henlius finances and drives 100% of the expensive clinical trials. Alligator receives the money as pure profit without having development costs themselves. Timeline (When does the money arrive?) The revenues are directly linked to how fast Henlius can drive the clinical trials through to approval: 1. Additional milestone payments (Short to medium term): Alligator will receive ongoing partial payments as the ongoing global Phase 3 study (HLX22-GC-301) progresses, including when data cuts take place and when official marketing authorization applications (BLA/NDA) are submitted to health authorities (such as the FDA and EMA). 2. The major royalty revenues (Longer term): The annual million amounts in royalties will only start rolling in when HLX22 is officially approved and launched on the market. Since the global Phase 3 study for gastric cancer was initiated in 2025, it will typically take a couple of years of patient follow-up and data processing. Financial analysts point out that Alligator is on track to present a real financial surplus in step with the maturation of the study. Disclaimer: I own shares in Alligator Bioscience and this is not a solicitation to either buy or sell shares in the company. Do your own analyses, I may be wrong in what I write and AI can also be wrong in what it has found.
·3 päivää sittenCEO Sören Bregenholt leaves Alligator 🚶➡️ https://www.di.se/mobil/nyheter/utbombade-forskningsbolagets-vd-lamnar/Positive that he is leaving and that they now just have to wait for the study regarding HLX22. Wild that it has been traded all the way down to just about 62 million SEK in market cap after the latest capital raise. Solely if HLX22 gets approved it should lift Alligator massively. Less than a year ago the research in Mitazalimab was valued to be worth several billion now it is valued to be worth 0. HLX22 should be worth a lot of money, with an estimated revenue to Alligator Bioscience AB of between 150-450 million SEK at peak sales Alligator Bioscience AB should as a minimum be able to move above 1 billion SEK in market cap if HLX22 gets approved and why shouldn't it get approved ? It has Orphan Drug designation and Henlius is putting many hundreds of millions of kroner into the current phase 3 trial and so far there have been convincing results. I am staying in the stock at least and waiting for the coming year's research results. Alligator Bioscience is also in line for some hefty milestone payments if the research results hit the target. Disclaimer: I own shares in Alligator Bioscience and this is not a call to neither buy nor sell shares in the company. Do your own analyses, I can be wrong in what I write and AI can be wrong.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 24 214 744 | 24 214 744 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 24 214 744 | 24 214 744 | 0 | 0 |
2026 Q2 - tulosraportti
43 päivää sitten
‧42 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 päivä sittenI asked AI and got this answer: what is alligator expected to earn and when on the agreement regarding HLX22 According to the current agreement structure, the Swedish biotech company Alligator Bioscience is entitled to 35% of all milestone payments and royalties that the company AbClon receives from Shanghai Henlius Biotech for the development and sale of HLX22. Following a major strategic realignment in the summer of 2026, where Alligator stopped the in-house development of their previous lead candidate mitazalimab, the HLX22 agreement now constitutes the single most important value creator for the company. Here are the details on what Alligator is expected to earn, as well as when the money will arrive: Expected revenues (What can they earn?) • Historical milestones: Alligator has so far received a total of 3 million USD in early milestone payments under the agreement. • Effective royalty rate: The agreement ensures Alligator an effective royalty of 1.5% to 2.0% (more precisely up to 1.75%) of the total global net sales of HLX22. • Annual potential at peak sales (Peak Sales): Alligator estimates itself that when HLX22 is fully rolled out on the market, it will be able to generate 150 to 450 million Swedish kronor (SEK) annually in pure royalty income – based solely on the gastric cancer indication. • No costs: The absolute major financial advantage is that Henlius finances and drives 100% of the expensive clinical trials. Alligator receives the money as pure profit without having development costs themselves. Timeline (When does the money arrive?) The revenues are directly linked to how fast Henlius can drive the clinical trials through to approval: 1. Additional milestone payments (Short to medium term): Alligator will receive ongoing partial payments as the ongoing global Phase 3 study (HLX22-GC-301) progresses, including when data cuts take place and when official marketing authorization applications (BLA/NDA) are submitted to health authorities (such as the FDA and EMA). 2. The major royalty revenues (Longer term): The annual million amounts in royalties will only start rolling in when HLX22 is officially approved and launched on the market. Since the global Phase 3 study for gastric cancer was initiated in 2025, it will typically take a couple of years of patient follow-up and data processing. Financial analysts point out that Alligator is on track to present a real financial surplus in step with the maturation of the study. Disclaimer: I own shares in Alligator Bioscience and this is not a solicitation to either buy or sell shares in the company. Do your own analyses, I may be wrong in what I write and AI can also be wrong in what it has found.
- ·3 päivää sittenCEO Sören Bregenholt leaves Alligator 🚶➡️ https://www.di.se/mobil/nyheter/utbombade-forskningsbolagets-vd-lamnar/Positive that he is leaving and that they now just have to wait for the study regarding HLX22. Wild that it has been traded all the way down to just about 62 million SEK in market cap after the latest capital raise. Solely if HLX22 gets approved it should lift Alligator massively. Less than a year ago the research in Mitazalimab was valued to be worth several billion now it is valued to be worth 0. HLX22 should be worth a lot of money, with an estimated revenue to Alligator Bioscience AB of between 150-450 million SEK at peak sales Alligator Bioscience AB should as a minimum be able to move above 1 billion SEK in market cap if HLX22 gets approved and why shouldn't it get approved ? It has Orphan Drug designation and Henlius is putting many hundreds of millions of kroner into the current phase 3 trial and so far there have been convincing results. I am staying in the stock at least and waiting for the coming year's research results. Alligator Bioscience is also in line for some hefty milestone payments if the research results hit the target. Disclaimer: I own shares in Alligator Bioscience and this is not a call to neither buy nor sell shares in the company. Do your own analyses, I can be wrong in what I write and AI can be wrong.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 000 | - | - | ||
| 65 042 | - | - | ||
| 100 000 | - | - | ||
| 100 000 | - | - | ||
| 100 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 5.5. | ||
2025 Q4 - tulosraportti 12.2. | ||
2025 Q3 - tulosraportti 23.10.2025 | ||
2025 Q2 - tulosraportti 10.7.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 24 214 744 | 24 214 744 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 24 214 744 | 24 214 744 | 0 | 0 |
2026 Q2 - tulosraportti
43 päivää sitten
‧42 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 5.5. | ||
2025 Q4 - tulosraportti 12.2. | ||
2025 Q3 - tulosraportti 23.10.2025 | ||
2025 Q2 - tulosraportti 10.7.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 päivä sittenI asked AI and got this answer: what is alligator expected to earn and when on the agreement regarding HLX22 According to the current agreement structure, the Swedish biotech company Alligator Bioscience is entitled to 35% of all milestone payments and royalties that the company AbClon receives from Shanghai Henlius Biotech for the development and sale of HLX22. Following a major strategic realignment in the summer of 2026, where Alligator stopped the in-house development of their previous lead candidate mitazalimab, the HLX22 agreement now constitutes the single most important value creator for the company. Here are the details on what Alligator is expected to earn, as well as when the money will arrive: Expected revenues (What can they earn?) • Historical milestones: Alligator has so far received a total of 3 million USD in early milestone payments under the agreement. • Effective royalty rate: The agreement ensures Alligator an effective royalty of 1.5% to 2.0% (more precisely up to 1.75%) of the total global net sales of HLX22. • Annual potential at peak sales (Peak Sales): Alligator estimates itself that when HLX22 is fully rolled out on the market, it will be able to generate 150 to 450 million Swedish kronor (SEK) annually in pure royalty income – based solely on the gastric cancer indication. • No costs: The absolute major financial advantage is that Henlius finances and drives 100% of the expensive clinical trials. Alligator receives the money as pure profit without having development costs themselves. Timeline (When does the money arrive?) The revenues are directly linked to how fast Henlius can drive the clinical trials through to approval: 1. Additional milestone payments (Short to medium term): Alligator will receive ongoing partial payments as the ongoing global Phase 3 study (HLX22-GC-301) progresses, including when data cuts take place and when official marketing authorization applications (BLA/NDA) are submitted to health authorities (such as the FDA and EMA). 2. The major royalty revenues (Longer term): The annual million amounts in royalties will only start rolling in when HLX22 is officially approved and launched on the market. Since the global Phase 3 study for gastric cancer was initiated in 2025, it will typically take a couple of years of patient follow-up and data processing. Financial analysts point out that Alligator is on track to present a real financial surplus in step with the maturation of the study. Disclaimer: I own shares in Alligator Bioscience and this is not a solicitation to either buy or sell shares in the company. Do your own analyses, I may be wrong in what I write and AI can also be wrong in what it has found.
- ·3 päivää sittenCEO Sören Bregenholt leaves Alligator 🚶➡️ https://www.di.se/mobil/nyheter/utbombade-forskningsbolagets-vd-lamnar/Positive that he is leaving and that they now just have to wait for the study regarding HLX22. Wild that it has been traded all the way down to just about 62 million SEK in market cap after the latest capital raise. Solely if HLX22 gets approved it should lift Alligator massively. Less than a year ago the research in Mitazalimab was valued to be worth several billion now it is valued to be worth 0. HLX22 should be worth a lot of money, with an estimated revenue to Alligator Bioscience AB of between 150-450 million SEK at peak sales Alligator Bioscience AB should as a minimum be able to move above 1 billion SEK in market cap if HLX22 gets approved and why shouldn't it get approved ? It has Orphan Drug designation and Henlius is putting many hundreds of millions of kroner into the current phase 3 trial and so far there have been convincing results. I am staying in the stock at least and waiting for the coming year's research results. Alligator Bioscience is also in line for some hefty milestone payments if the research results hit the target. Disclaimer: I own shares in Alligator Bioscience and this is not a call to neither buy nor sell shares in the company. Do your own analyses, I can be wrong in what I write and AI can be wrong.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 000 | - | - | ||
| 65 042 | - | - | ||
| 100 000 | - | - | ||
| 100 000 | - | - | ||
| 100 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 24 214 744 | 24 214 744 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 24 214 744 | 24 214 744 | 0 | 0 |